Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors

Iveric bio announced the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to shape the company’s business strategy and in overseeing the development and regulatory submission process for avacincaptad pegol (ACP, also known as Zimura) since he joined Iveric Bio in 2020, according to a company news release.

“On behalf of the entire Board of Directors, we are excited to have Pravin join our board during this pivotal time as the Company prepares for a potential approval and commercial launch of ACP in geographic atrophy,” said Adrienne L. Graves, PhD, Chairman of the Board of Iveric Bio.

“Pravin is an exceptional leader whose skills as an executive and extensive knowledge as a retinal specialist provide a valued perspective that will enhance the collective experience of our Board,” stated Glenn P. Sblendorio, Chief Executive Officer of Iveric Bio. “I enjoy working closely with Pravin and now look forward to working with him in his added role as a board member. We are committed to executing our plan to deliver value to our shareholders.”